NIPH Clinical Trials Search

oral luteoin treatment in localized prostate cancer receiving active surveillance

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	In cases occurred with severe adverse events, or rapid worsening of prostate cancer
Date of first enrollment	08/01/2026
Target sample size	40
Countries of recruitment
Study type	Interventional
Intervention(s)	50mg /day oral luteolin treatment in one year

Outcome(s)

Primary Outcome	rate of worsening of prostate cancer under active surveillance
Secondary Outcome	adverse events, or microRNA status

Key inclusion & exclusion criteria

Age minimum	>= 20age old
Age maximum	Not applicable
Gender	Male
Include criteria	1. patients receiving active surveillance 2. initial PSA less than 20, less than cT2b 3. patients obtained informed consent 4. male patients whose age is more than 20 5. ECOG-PS less than 1
Exclude criteria	1. patients with dimentia 2. patients with serious infection 3. patients with hepatic dyscunction (Child-Pugh criteria B, C) 4. patients with severe renal dysfunction 5. patients with inadequate designated by responsible doctor